Markets
← Back to Stocks
BSX
BOSTON SCIENTIFIC CORP
Health Care · Health Care Equipment
$70.04
-1.74%
Vol: 0.1M
Araverus Market Read
Thursday, March 19, 2026
Morgan Stanley reiterates Buy as Boston Scientific pursues China stroke market expansion.
Boston Scientific faces investor lawsuits and lowered price targets from Truist ($92 from $95) and UBS ($105 from $120), but Morgan Stanley reiterated a Buy rating. The company is targeting China's stroke market with ENROUTE-WALLSTENT registry expansion. Pre-market stock fell 0.90% to $69.75 with 35 analysts recommending buys against 0 sells, averaging $103.82 target.
Price 50d 200d
Previous Market Reads
2 of 2 days↓
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$103.7B
P/E (TTM)36.0
Forward P/E17.9
Beta0.70
Div Yield—
Prev Close$71.28
RSI (14-Day)
27Oversold
0305070100
52-Week Range
$67.56$70.04$109.50
From High-36.0%
From Low+3.7%
Moving Averages
50d SMA
$81.00-13.5%
200d SMA
$95.92-27.0%
Price below 200d MA — bearish structure.
Returns
1W
+2.2%
1M
-8.2%
3M
-24.6%
6M
-28.9%
1Y
-29.4%
YTD
-26.1%
Volume
Today123K
20d Avg12.8M
Ratio0.01x